

Plough for 24 to 36 months or until Schering-Plough obtains USDA approvals. The consent order also prohibits AHP from suing Schering-Plough for patent infringements relating to the vaccines.

DATES: Complaint and Order issued May 16, 1997.¹

FOR FURTHER INFORMATION CONTACT: Casey Triggs, FTC/S-2308, Washington, D.C. 20580. (202) 326-2804

SUPPLEMENTARY INFORMATION: On Wednesday, March 5, 1997, there was published in the **Federal Register**, 62 FR 10058, a proposed consent agreement with analysis In the Matter of American Home Products Corporation, for the purpose of soliciting public comment. Interested parties were given sixty (60) days in which to submit comments, suggestions or objections regarding the proposed form of the order.

No comments having been received, the Commission has ordered the issuance of the complaint in the form contemplated by the agreement, made its jurisdictional findings and entered an order to cease and divest, as set forth in the proposed consent agreement, in disposition of this proceeding.

(Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interpret or apply sec. 5, 38 Stat. 719, as amended; sec. 7, 38 Stat. 731, as amended; 15 U.S.C. 45, 18)

Benjamin I. Berman,

Acting Secretary.

[FR Doc. 97-17755 Filed 7-7-97; 8:45 am]

BILLING CODE 6750-01-M

FEDERAL TRADE COMMISSION

[Dkt. C-3741]

Schering-Plough Healthcare Products, Inc.; Prohibited Trade Practices, and Affirmative Corrective Actions

AGENCY: Federal Trade Commission.

ACTION: Consent order.

SUMMARY: In settlement of alleged violations of federal law prohibiting unfair or deceptive acts or practices and unfair methods of competition, this consent order prohibits, among other things, the Tennessee-based manufacturer of health care products from making certain claims about the effectiveness or length of protection provided by any children's sun protection product unless they possess scientific evidence to substantiate the claims, and from misrepresenting the existence, contents, validity, results or conclusions of any test or study

¹ Copies of the Complaint and the Decision and Order are available from the Commission's Public Reference Branch, H-130, 6th Street & Pennsylvania Avenue, N.W., Washington, D.C. 20580.

concerning sun protection products. The consent order requires the respondent to produce and distribute 150,000 consumer education brochures regarding sunscreen protection for children.

DATES: Complaint and Order issued May 16, 1997.¹

FOR FURTHER INFORMATION CONTACT: Mamie Kresses, FTC/S-4002, Washington, D.C. 20580. (202) 326-2070.

SUPPLEMENTARY INFORMATION: On Wednesday, March 5, 1997, there was published in the **Federal Register**, 62 FR 10059, a proposed consent agreement with analysis In the Matter of Schering-Plough Healthcare Products, Inc., for the purpose of soliciting public comment. Interested parties were given sixty (60) days in which to submit comments, suggestions or objections regarding the proposed form of the order.

No comments having been received, the Commission has ordered the issuance of the complaint in the form contemplated by the agreement, made its jurisdictional findings and entered an order to cease and to desist, as set forth in the proposed consent agreement, in disposition of this proceeding.

(Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interpret or applies sec. 5, 38 Stat. 719, as amended; 15 U.S.C. 45, 52)

Benjamin I. Berman,

Acting Secretary.

[FR Doc. 97-17756 Filed 7-7-97; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 735]

FY 1997 Epidemiologic Research Studies of Acquired Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV) Infection

Introduction

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 1997 funds for a cooperative agreement program for epidemiologic and behavioral research studies of AIDS and HIV infection. These include studies to examine factors related to: (I)

¹ Copies of the Complaint, the Decision and Order and statements by Commissioners Azcuenaga and Starek are available from the Commission's Public Reference Branch, H-130, 6th Street & Pennsylvania Avenue, N.W., Washington, D.C. 20580.

manifestations and medical management of HIV infection in children and (II) acceptability of new prevention methods currently being tested that offer alternatives to male condoms for HIV/STD protection. The study of these research areas as they pertain to racial and ethnic minority populations (defined as Alaskan Native, African-American, Hispanic, Asian/Pacific Islander, and American Indian) is encouraged because minorities constitute more than 53 percent of all reported cases of AIDS and approximately 77 percent of all women and children with AIDS.

CDC is committed to achieving the health promotion and disease prevention objectives of Healthy People 2000, a national activity to reduce morbidity and mortality and improve the quality of life. This announcement is related to the priority area of HIV Infection. (To order a copy of "Healthy People 2000," see the section Where to Obtain Additional Information.)

Authority

This program is authorized under Sections 301(a) and 317(k)(2) of the Public Health Service Act [42 U.S.C. 241(a) and 247b(k)(2)], as amended. Applicable program regulations are set forth in 42 CFR Part 52, entitled "Grants for Research Projects."

Smoke-Free Workplace

CDC strongly encourages all cooperative agreement recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, and early childhood development services are provided to children.

Eligible Applicants

Eligible applicants include all public and private nonprofit organizations and governments and their agencies. Thus, universities; colleges; research institutions; hospitals and other public and private organizations; territories, District of Columbia, and State and local governments or their bona fide agents; federally recognized Indian tribal governments; Indian tribes or Indian tribal organizations; and small minority- or women-owned nonprofit businesses are eligible to apply.

Note: Organizations described in section 501(c)(4) of the Internal Revenue Code of 1986 that engage in lobbying are not eligible to receive Federal grant/cooperative agreement funds.